NLRP3 inhibitor progam (BioAge Labs)

N/A

Report date: 2025/01/26 17:30:23
NME

Base Information

Drug NameNLRP3 inhibitor progam (BioAge Labs)
Drug Alias NameCNS oral drug
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsHealthy AgingParkinson DiseaseCentral Nervous System Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBioAge Labs Inc
China Registration ClassN/A

Develop Information

Active CompaniesBioAge Labs Inc
Inactive CompaniesN/A
Active IndicationsHealthy AgingParkinson DiseaseCentral Nervous System Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A